Name: Presentation by Aaron Bailey, AbCellera: Leveraging the Versatility of Size Exclusion Coupled to Mass Spectrometry (SEC-MS) to Accelerate Antibody Drug Development
Start: 2024-10-30T08:00:00-07:00
End: 2024-10-30T09:00:00-07:00

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

There are no events on this day.

September 28

September 28, 2023 @ 8:00 am - 9:00 am

Presentation by Brian Gau, Pfizer: Oligonucleotide Mapping via LC-UV-MS/MS to Enable Comprehensive Primary Structure Characterization of mRNA Drug Substance

There are no events on this day.

There are no events on this day.

0 events, 27

0 events, 27

0 events, 28

0 events, 28

0 events, 29

0 events, 29

0 events, 30

0 events, 30

0 events, 31

0 events, 31

0 events, 1

0 events, 1

0 events, 2

0 events, 2

0 events, 3

0 events, 3

0 events, 4

0 events, 4

0 events, 5

0 events, 5

0 events, 6

0 events, 6

0 events, 7

0 events, 7

0 events, 8

0 events, 8

0 events, 9

0 events, 9

0 events, 10

0 events, 10

0 events, 11

0 events, 11

0 events, 12

0 events, 12

0 events, 13

0 events, 13

0 events, 14

0 events, 14

0 events, 15

0 events, 15

0 events, 16

0 events, 16

0 events, 17

0 events, 17

0 events, 18

0 events, 18

0 events, 19

0 events, 19

0 events, 20

0 events, 20

0 events, 21

0 events, 21

0 events, 22

0 events, 22

0 events, 23

0 events, 23

0 events, 24

0 events, 24

0 events, 25

0 events, 25

0 events, 26

0 events, 26

0 events, 27

0 events, 27

1 event, 28

1 event, 28

Presentation by Brian Gau, Pfizer: Oligonucleotide Mapping via LC-UV-MS/MS to Enable Comprehensive Primary Structure Characterization of mRNA Drug Substance

Presentation by Brian Gau, Pfizer: Oligonucleotide Mapping via LC-UV-MS/MS to Enable Comprehensive Primary Structure Characterization of mRNA Drug Substance

0 events, 29

0 events, 29

0 events, 30

0 events, 30

Presentation by Brian Gau, Pfizer: Oligonucleotide Mapping via LC-UV-MS/MS to Enable Comprehensive Primary Structure Characterization of mRNA Drug Substance